-
News | 2020.07.27
A new biotechnology tool to tackle antibiotic resistance
Designing effective new molecules to tackle infectious diseases is a difficult process that currently represents a huge challenge for scientists, especially given the rise in bacterial resistance to antibiotics. Scientists from the Institut Pasteur's Bacterial Genome Plasticity Unit have responded to this challenge by developing a new biotechnological tool which bypasses the sampling limitations...
-
News | 2020.05.20
Blood test: a potential new tool for controlling infections
A new technique could provide vital information about a community’s immunity to infectious diseases including malaria and Covid-19.The diagnostic test analyses a blood sample to reveal immune markers that indicate whether – and when – a person was exposed to an infection. It was developed to track malaria infections in communities, to assist in the elimination of deadly ‘relapsing’ malaria, but...
-
Document de presse | 2020.05.26
MV-SARS-CoV-2 vaccine candidate: a new partnership between Institut Pasteur, CEPI, Thémis and MSD
Institut Pasteur announces recent advances in the development of one of its candidate vaccines, MV-SARS-CoV-2, using the measles vector, as part of a renewed partnership with CEPI and the companies Thémis and MSD.With over 100 vaccine projects in development worldwide, the development of a vaccine against SARS CoV-2 infection remains a challenge, with many scientific uncertainties ahead. The...
-
Page avancée | 2020.05.26
2019 Theses and Ceremony
2019 Theses and Ceremony
-
News | 2020.05.26
Tiger mosquito in France: 58 départements on red alert
In early May 2020, the French health authorities placed 58 of the country's départements on "red alert" in their map showing the spread of the tiger mosquito in France – seven more than in 2019. The Aedes albopictus mosquito, originally from Asia, has been present in France since 2004. It is the vector for diseases such as dengue, chikungunya and Zika.The tiger mosquito (...
-
Document de presse | 2020.05.26
COVID-19: the vast majority of patients with a minor form develop neutralizing antibodies
Teams from Strasbourg University Hospital and the Institut Pasteur carried out a study among hospital staff on the two sites of Strasbourg University Hospital. After observing 160 people with minor forms of COVID-19, the scientists concluded that nearly all the patients developed antibodies within two weeks of being infected. In 98% of the patients, neutralizing antibodies were detected after 28...
-
News | 2020.06.02
The hidden population of multidrug-resistant Klebsiella bacteria colonizing the human digestive tract
Klebsiella bacteria are responsible for some of the most antibiotic-resistant infections. A major study on intestinal colonization by Klebsiella has shed light on human carriage of these strains in the community (i.e. outside hospitals) in low-income countries. This study reveals that controlling Klebsiella carriage is a complex challenge.It is normal to find Klebsiella bacteria inhabiting the...
-
News | 2020.06.05
Covid-19: a study in children with hyper-inflammatory syndrome related to Kawasaki disease
The team of the Department of General Pediatrics and Infectious Diseases of the Necker-Enfants Malades AP-HP Hospital, the Institut Pasteur, Inserm and the University of Paris, conducted a prospective observational study between April 27 and May 15, 2020 to describe the characteristics of children and adolescents hospitalized in a context of Kawasaki disease-like syndrome in a COVID-19 epidemic...
-
News | 2020.06.04
Study reveals conditions for the onset of severe forms of COVID-19
Using state-of-the-art sequencing and bioinformatics techniques, scientists from the Institut Pasteur, working with fellow scientists from Israel and China, determined that patients with severe forms of COVID-19 presented an abnormal, ineffective lymphocyte response and a massive infiltration of inflammatory cells in the lungs.Patients with COVID-19 (see the COVID-19 fact sheet)present a...
-
News | 2020.06.10
Small intestine regulates immune surveillance of colorectal cancer during chemotherapy treatment
An international study has demonstrated that the microbiota and the intestinal cell death triggered by chemotherapy stimulate the efficacy of the immune response in patients with colorectal cancer. The results of the study, conducted in France by scientists from Gustave Roussy, Inserm, Université Paris-Saclay, the Institut Pasteur, IHU Méditerranée Infection and INRAE, were published in the...
